OP107
Anti-BRCA1 (Ab-4) Mouse mAb (SD118)
liquid, clone SD118, Calbiochem®
Synonyme(s) :
Anti-Breast Cancer Susceptibility Protein
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.43
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified antibody
Type de produit anticorps
primary antibodies
Clone
SD118, monoclonal
Forme
liquid
Contient
≤0.1% sodium azide as preservative
Espèces réactives
human
Fabricant/nom de marque
Calbiochem®
Conditions de stockage
do not freeze
Isotype
IgG1
Conditions d'expédition
wet ice
Température de stockage
2-8°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... BRCA1(672)
Description générale
Anti-BRCA1 (Ab-4), mouse monoclonal, clone SD118, recognizes the ~220 kDa BRCA1 in HBL-100 and SK-BR3 cells. It is validated for WB, IF, IP, and for frozen sections.
Purified mouse monoclonal antibody generated by immunizing RBF/DnJ mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells (see application references). Recognizes the ~220 kDa BRCA1 protein.
Recognizes the ~220 kDa BRCA1 protein in HBL-100 and SK-BR3 cells. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
Immunogène
Human
a recombinant polypeptide corresponding to amino acids 1005-1313 in exon 11 of human BRCA1
Application
Frozen Sections (2 µg/ml)
Immunoblotting (2 µg/ml, see application references)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (2 µg, see application references)
Paraffin Sections (not recommended)
Immunoblotting (2 µg/ml, see application references)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (2 µg, see application references)
Paraffin Sections (not recommended)
Conditionnement
Please refer to vial label for lot-specific concentration.
Avertissement
Toxicity: Standard Handling (A)
Forme physique
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Remarque sur l'analyse
Positive Control
HBL-100 or SK-BR3 cells
HBL-100 or SK-BR3 cells
Autres remarques
Chen, J.J., et al. 1999. Cancer Res.59, 1752s.
Cressman, V.L., et al. 1999. Cell Growth Differ.10, 1.
Irminger-Finger, I., et al. 1999. Biol. Chem.380, 117.
Xu, X., et al. 1999. Nat. Genet.22, 37.
Wilson, C.A., et al. 1999. Nat. Genet.21, 236.
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Fan, S., et al. 1998. Int. J. Cancer77, 600.
Gowen, L.C., et al. 1998. Science281, 1009.
Hsu, L.C. and R.L. White. 1998. Proc. Natl. Acad. Sci. USA95, 12983.
Shen, S.X., et al. 1998. Oncogene17, 3115.
Tulchin, N., et al. 1998. Int. J. Oncol.13, 513.
Ludwig, T., et al. 1997. Genes Dev11, 1226.
Ruffner, H. and I.M. Verma. 1997. Proc. Natl. Acad. Sci. USA94, 7138.
Scully, R., et al. 1997. Cell90, 425.
Thakur, S., et al. 1997. Mol. Cell Biol.17, 444.
Wilson, C.A., et al. 1997. Oncogene14, 1.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin Oncol.23, 1.
Chen, Y., et al. 1996. Cancer Res.56, 3168.
Liu, C.Y., et al. 1996. Genes Dev.10, 1835.
Gudas, J.M., et al. 1996. Cell Growth Differ.7, 717.
Scully, R., et al. 1996. Science272, 123.
Vaughn, J.P., et al. 1996. Cell Growth Differ.7, 711.
Wilson, C.A. et al. 1996. Nat. Genet.13, 264.
Thompson, M.E., et al. 1995. Nat. Genet.9, 444.
Miki, Y., et al. 1994. Science266, 66.
Cressman, V.L., et al. 1999. Cell Growth Differ.10, 1.
Irminger-Finger, I., et al. 1999. Biol. Chem.380, 117.
Xu, X., et al. 1999. Nat. Genet.22, 37.
Wilson, C.A., et al. 1999. Nat. Genet.21, 236.
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Fan, S., et al. 1998. Int. J. Cancer77, 600.
Gowen, L.C., et al. 1998. Science281, 1009.
Hsu, L.C. and R.L. White. 1998. Proc. Natl. Acad. Sci. USA95, 12983.
Shen, S.X., et al. 1998. Oncogene17, 3115.
Tulchin, N., et al. 1998. Int. J. Oncol.13, 513.
Ludwig, T., et al. 1997. Genes Dev11, 1226.
Ruffner, H. and I.M. Verma. 1997. Proc. Natl. Acad. Sci. USA94, 7138.
Scully, R., et al. 1997. Cell90, 425.
Thakur, S., et al. 1997. Mol. Cell Biol.17, 444.
Wilson, C.A., et al. 1997. Oncogene14, 1.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin Oncol.23, 1.
Chen, Y., et al. 1996. Cancer Res.56, 3168.
Liu, C.Y., et al. 1996. Genes Dev.10, 1835.
Gudas, J.M., et al. 1996. Cell Growth Differ.7, 717.
Scully, R., et al. 1996. Science272, 123.
Vaughn, J.P., et al. 1996. Cell Growth Differ.7, 711.
Wilson, C.A. et al. 1996. Nat. Genet.13, 264.
Thompson, M.E., et al. 1995. Nat. Genet.9, 444.
Miki, Y., et al. 1994. Science266, 66.
Maximal BRCA1 levels are observed in subconfluent cell populations after serum stimulation. Highly specific BRCA1 antibody useful for blotting and IP of full length BRCA1 protein. Antibody should be titrated for optimal results in individual systems.
Informations légales
Sold under license of U.S. Patents 5,753,441 and 6,162,897.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Outil de sélection de produits.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 1
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Veronica Gomez Godinez et al.
PloS one, 15(4), e0227849-e0227849 (2020-04-29)
Understanding the mitotic DNA damage response (DDR) is critical to our comprehension of cancer, premature aging and developmental disorders which are marked by DNA repair deficiencies. In this study we use a micro-focused laser to induce DNA damage in selected
M Tanikawa et al.
British journal of cancer, 104(8), 1349-1355 (2011-03-17)
The TFII-I is a multifunctional transcriptional factor known to bind specifically to several DNA sequence elements and to mediate growth factor signalling. A microdeletion at the chromosomal location 7q11.23 encoding TFII-I and the related family of transcription factors may result
Myth T S Mok et al.
Traffic (Copenhagen, Denmark), 13(6), 800-814 (2012-03-17)
The breast cancer associated gene 1 (BRCA1)-A protein complex assembles at DNA damage-induced nuclear foci to facilitate repair of double-stranded breaks. Here, we describe the first systematic comparison of the dynamics, copy number and organization of its core components at
Amandine I Garcia et al.
EMBO molecular medicine, 3(5), 279-290 (2011-04-08)
Germ-line mutations in the BRCA1 gene strongly predispose women to breast cancer (lifetime risk up to 80%). Furthermore, the BRCA1 protein is absent or present at very low levels in about one third of sporadic breast cancers. However, the mechanisms
Maria C Villarroel et al.
Molecular cancer therapeutics, 10(1), 3-8 (2010-12-08)
Metastasis and drug resistance are the major causes of mortality in patients with pancreatic cancer. Once developed, the progression of pancreatic cancer metastasis is virtually unstoppable with current therapies. Here, we report the remarkable clinical outcome of a patient with
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique